We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-5.11%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$549M
AUM Growth
+$38.2M
Cap. Flow
+$95.8M
Cap. Flow %
17.45%
Top 10 Hldgs %
48.43%
Holding
55
New
15
Increased
11
Reduced
10
Closed
13

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$42.1M
2
PTCT icon
PTC Therapeutics
PTCT
+$18.6M
3
ALKS icon
Alkermes
ALKS
+$13.6M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$13.1M
5
REPL icon
Replimune Group
REPL
+$12.5M

Top Sells

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$20.9M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$12.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$9.7M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$9.31M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$6.65M

Sector Composition

Rank Sector Weight
1 Healthcare 96.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
51
Rhythm Pharmaceuticals
RYTM
$6.81B
– –
-772,000
Closed -$12.7M
TVTX icon
52
Travere Therapeutics
TVTX
$5.2B
– –
-60,000
Closed -$922K
VKTX icon
53
Viking Therapeutics
VKTX
$3.7B
– –
-598,550
Closed -$9.7M
XENE icon
54
PUT
Xenon Pharmaceuticals
XENE
$6.06B
– –
-2,700
Closed -$104K
ICPT
55
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-601,322
Closed -$6.65M
1 2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Great Point Partners held 55 positions worth $549M, up 7.5% from $511M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Great Point Partners deployed $95.8M of net new capital in Q3 2023, opening 15 new positions and adding to 11 existing holdings. Its largest new stake was UroGen Pharma: 2,620,545 shares worth $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Gracell Biotechnologies Inc. American Depositary Shares, an estimated $6.17M trimmed.

  • Great Point Partners's largest Q3 2023 buy was UroGen Pharma: 2,620,545 shares worth $36.7M.
  • Great Point Partners added most to Alkermes in Q3 2023, an estimated $13.6M increase.
  • Great Point Partners's biggest Q3 2023 reduction was Gracell Biotechnologies Inc. American Depositary Shares, cutting an estimated $6.17M.
  • Great Point Partners fully exited Amylyx Pharmaceuticals in Q3 2023, selling an estimated $20.9M.
  • Great Point Partners's ten largest holdings make up 48% of its $549M portfolio in Q3 2023.
  • Great Point Partners opened 15 new positions and closed 13 in Q3 2023.
  • Great Point Partners's portfolio value rose 7.5% quarter-over-quarter to $549M.

Based on Great Point Partners's 13F filing for Q3 2023, filed 14 Nov 2023.